

ASX Announcement

Race to present at TechKnow Invest Roadshow in Sydney and Melbourne during July 2024

25 July 2024 – Race Oncology Limited (“Race”) is pleased to invite investors in Sydney and Melbourne to join us in person at the TechKnow Invest Roadshow on 30 July 2024 in Sydney and 31 July 2024 in Melbourne.

TechKnow Investor Roadshow will feature ASX-listed tech and medtech companies, showcasing investment opportunities within the sector and providing network space for all attendees. Race Executive Director, Dr Pete Smith and CEO, Dr Daniel Tillett will both be present at the two-day conference. Shareholders and investor attendees are invited to register for free to attend the event, as well as to meet and speak with Dr Smith and Dr Tillett at Race’s kiosk.

Race will also give investor presentations on both days of the conference, discussing Race’s bisantrene program and upcoming milestones, as well as cancer survivorship and the importance of cardioprotection in cancer treatment.

Conference details

Sydney

30 July 2024 at Swissôtel Sydney, NSW. | Race is presenting at 2.45pm.

Melbourne

31 July 2024 at Rydges Melbourne, VIC. | Race is presenting at 10.30am.

The full conference program can be found [here](#). Investors who wish to join us can register for their free passes via [this link](#).

The Race team looks forward to meeting attendees in person.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.



Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 bisantrene as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au